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Abstract
Objectives: To compare the effectiveness of two dosing regimens of vaginal misoprostol for cervical ripening and 
induction of labour.
Materials and Methods: Pregnant women with singleton low risk pregnancy at term scheduled for elective induction 
of labour were randomized to receive either 25 µg or 50 µg of vaginal misoprostol for pre‑labour cervical ripening. All 
the patients received antenatal care and delivered at the University College Hospital (UCH) from January 1st to May 
31st 2006. A total of 128 patients were randomized; 65 patients received 25 µg and 63 patients received 50 µg of vaginal 
misoprostol.
Results: Significantly higher number of patients in the 50 µg group progressed to active labour as compared with 
the 25 µg group (95.2% versus 84.6%, P < 0.05). The need for oxytocin augmentation of labour was higher among 
the 25 µg as compared with 50 µg (39.7% versus 16.4%, P = 0.007). There was higher proportion of patients in the 
50 µg group delivering vaginally within 24 hours as compared with the 25 µg group (98.2% versus 90.0%, P = 0.063). 
However, the mean interval between the first dose of misoprostol and vaginal delivery was not statistically different in 
the two groups (754 ± 362 minutes and 885 ± 582 minutes, P = 0.152). The incidence of caesarean section was similar 
in the two groups (7.7% versus 11%, P = 0.580). Labour complications, such as precipitate labour, tachysystole and 
abnormal fetal heart rate patterns were greater in the 50 µg group.
Conclusion: Twenty‑five microgram of misoprostol appears to be as effective as 50 µg for pre‑induction cervical 
ripening and labour induction. Though 50 µg of vaginal misoprostol resulted in relatively faster delivery and less need 
for oxytocin augmentation, it was associated with more labour complications as compared with 25 µg of misoprostol.
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Introduction
A major factor that influences successful induction of 
labour is the cervical status. If the cervix is unripe, closed, 
firm and uneffaced, with Bishop score less than 6, the 
conventional method of induction of labour by surgical 
amniotomy becomes technically difficult and intravenous 
infusion of oxytocin results in prolonged labour with 
risks of maternal and fetal complications, unsuccessful 
inductions and unnecessary increased rate of caesarean 
section.[1,2]
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While many methods have been described for cervical 
ripening,[3,4] recent efforts have been focused on the 
pharmacological agents mainly oxytocin and prostaglandins. 
Although oxytocin is a safe and effective initiator of uterine 
contractions, its success depends on prelabour cervical 
status.[5]
Misoprostol is a synthetic 15‑deoxy 16‑hydroxy, 16‑methyl 
analogue of the naturally occurring prostaglandin E1 that 
was originally manufactured for prevention and treatment 
of peptic ulcers diseases.[6] Several studies have found that 
misoprostol is effective as an agent for cervical ripening 
and induction of labour. It is inexpensive, easy to store, 
and stable at room temperature.[7] Despite many widely 
reported trials on misoprostol, several practical aspects of 
its administration are still yet to be well established and 
these include; the appropriate dosage, the dosing interval, 
and route of administration, with doses ranging from 
25 µg to 100 µg.[8,9] This study was designed to contribute 
to the ongoing research efforts on the appropriate use of 
misoprostol in obstetrics. It focused on comparison of two 
dosing regimens (25 µg versus 50 µg) of misoprostol for 
pre‑labour cervical ripening and induction of labour.
Materials and Methods
The study was a randomized trial on low risk singleton 
pregnant women, at term scheduled for elective induction 
of labor who received antenatal care and delivered at 
the University College Hospital (UCH), Ibadan during 
the study period. The study protocol was approved by 
the College of Medicine University of Ibadan and University 
College Hospital IRB. Adequate information was provided 
to the patients and they were properly counseled about 
the risks and benefits of misoprostol. Informed consent 
was obtained from each participant before inclusion 
in the study. Inclusion criteria were: (1) Singleton 
pregnancy at ≥37 weeks gestational age, (2) Bishop’s 
score of ≤5, (3) Cephalic presentation, (4) Reassuring 
fetal heart rate pattern, (6) Intact fetal membranes. The 
exclusion criteria were: (1) Mal‑presentation; (2) Multiple 
gestation, (3) Placenta praevia, (4) Estimated fetal weight 
of > 4000 g, (5) Non‑reassuring fetal heart rate, (6) Evidence 
of cephalo‑pelvic disproportion, (7) Any contraindication 
to receiving prostaglandins e.g. glaucoma and (8) Previous 
uterine surgery. All pregnancies were well‑dated with last 
menstrual periods and/or first trimester sonogram done to 
ascertain the appropriate gestational age.
They were then randomized using a computer generated 
random numbers into either the 25 µg group or the 50 µg 
group. The patients were assigned by means of table of 
random number with blocks of four to receive intra‑vaginal 
misoprostol of 25 µg or 50 µg (as prepared by the pharmacy 
unit of the University College Hospital, Ibadan). Group 
allocation was predetermined and placed in consecutively 
numbered and sealed opaque envelopes. Once a patient 
was deemed eligible and had signed the informed consent 
to participate in the study, she was assigned a sequential 
study number. The primary investigator, who was responsible 
for maintaining the envelopes, was contacted to open 
the corresponding numbered envelope for the purpose of 
treatment allocation.
The minimum sample size for each study arm was calculated 
to be 40 participants. However, a deliberate over sampling 
of 25% gave a total sample of 50 in each group. This 
corresponded to a statistical power of 80%, P = 0.05 at 
95% confidence level. One hundred and twenty‑eight (128) 
participants were enrolled in the study. None of the enrolled 
patients in the study withdrew. Sixty‑five (65) received 
25 µg and sixty‑three (63) received 50 µg of intra‑vaginal 
misoprostol.
The initial and subsequently Bishop Scores were assessed 
by the principal investigator. All those who fulfilled the 
study criteria received either 50 µg or 25 µg of intra‑vaginal 
misoprostol in the posterior fornix every 6 hours for a total of 
4 doses for cervical ripening or until satisfactory Bishop scores 
were established, with the maximum exposure time of 24 
hours. The participants were managed in labour by the routine 
Obstetricians covering the labour and delivery unit and used 
the standard protocol of care for any intervention in labour.
Management of labour
Oxytocin infusion and active management of labour were 
commenced in those patients with satisfactory Bishop 
Score (≥6) who did not enter active labour (defined as 
the occurrence of at least 3 strong uterine contractions in 
10 minutes each lasting 40‑60 seconds) after maximum 
exposure to either dose regimen, or had a spontaneous 
rupture of membranes without an ensuing adequate uterine 
contractions. Oxytocin infusion was not started until at 
least 4 hours after the last dose of misoprostol. By use of a 
standardized protocol, oxytocin titration was commenced 
at 4 miu/min and increased at intervals of 30 minutes to 
achieve adequate uterine contraction pattern of at least 3 
contractions in 10 minutes, each lasting for 40‑60 seconds.
At active phase of labour, routine intra‑partum labour 
managements were without regard to the dosing regimens. 
The fetal heart rates were monitored by intermittent 
auscultation or with hand held Doppler periodically. 
Primary outcomes were pre‑induction Bishop score, 
duration to achieve cervical ripening or onset of active 
labour, interval from first insertion of misoprostol to vaginal 
delivery, need for oxytocin augmentation, route of delivery, 
and Apgar scores. Secondary outcome measures were 
occurrence of uterine hypertonia, tachysystole, abnormal 
fetal heart rate, uterine rupture, and any other direct 
complications.
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Data analysis
Data collected were entered into a computer with a standard 
proforma of Statistical Package for Social Sciences (SPSS 
version 11.0). Statistical analysis was performed with 
Chi‑square for categorical variables, student’s t‑test for 
normally distributed continuous variables, Mann‑Whitney U 
for continuous variables that were not normally distributed. 
Fisher’s exact test with Yates correlation was performed 
whenever appropriate. All tests were two‑tailed (or sided) 
with a P = 0.05 considered as statistically significance.
Results
A total of 128 patients were enrolled in the study; 
65 patients received 25 µg and 63 patients received 50 µg 
of misoprostol. The maternal demographic characteristics 
were similar in both study groups. Post‑date pregnancy was 
the most common indication in both groups, accounting for 
71% and 76.2% for 25 µg and 50 µg groups respectively. 
The pre‑induction cervical assessments by the Bishop score 
in both groups were comparable [Table 1].
There was significantly higher proportion of patients in the 
50 µg group who progressed to active labour as compared with 
the 25 µg group (95.2% versus 84.6%, P = 0.049). The mean 
interval between the first dose of misoprostol and vaginal 
delivery is shorter in the 50 µg group (754 ± 362 minutes) 
than in the 25 µg group (885 ± 582 minutes), but it was not 
statistically significant (P = 0.152). There is no significant 
difference between the number of doses required to achieve 
favorable cervicalscore of >6 or active labour between the 
two groups 1.8 ± 1.1 for 25 µg group and 1.7 ± 0.7 for 
50 µg group (P = 0.689).
No patients in the either arm of the study group received the 
maximum dose of misoprostol to achieve a favorable Bishop 
score or active labour. The need for oxytocin augmentation 
among those who progressed to labour was higher in 
the 25 µg group (40.0%) than the 50 µg group (15.9% 
P = 0.007) [Table 2].
The incidence of caesarean section was similar in the two 
groups 7.7% and 11.0% for 25 µg group and 50 µg group 
respectively. More patients had caesarean section for poor 
progress of labour in the 25 µg group than in the 50 µg 
group while more patients had caesarean section on account 
of abnormal fetal heart rate in the 50 µg group. However, 
neither of these differences assumed statistical significance 
level [Table 2]. The overall rate of successful vaginal delivery 
and the rate of caesarean delivery were similar between the 
two groups [Table 2].
Adverse labour outcomes were mainly tachysystole (defined 
as the occurrence of more than five contractions in ten 
minutes for two consecutive ten minutes period), precipitate 
labour (delivery less than three hours after onset of labour), 
fetal distress and meconium stained liquor. All these were 
significantly higher in the 50 µg group (P = 0.03 8) [Table 3].
The birth weights of the neonates were similar in the two 
groups 3143 ± 475gm in 25 µg group and 3237 ± 486 in 
50 µg group (P = 0.291). The Apgar score of the neonates at 
one minute and five minutes were not statistically different. 
The overall fetal outcomes were not statistically different 
in the two groups.
Table 1: Cervical assessment by bishops score
Bishop score 25 µg (n=65) 50 µg (n=63) Significance***
Pre‑ripening/
induction score
1 3 (4.6%) 2 (3.2%) P=0.581
2 6 (9.2%) 5 (7.9%) P=0.347
3 22 (33.9%) 22 (34.9%) P=0.892 
4 23 (35.4%) 24 (38.2%) P=0.673




Data presented as n (%) or Mean+SD, ***Mann‑Whitney U‑test






Onset of labor during ripening 55 (84.6%) 60 (95.2%) P=0.049*
Need for oxytocin augmentation 26 (40%) 10 (15.9%) P=0.007*
Mode of delivery
Vaginal delivery 60 (92.3%) 56 (88.9%) P=0.580*
Caesarean section 5 (7.7%) 7 (11.1%) P=0.382*
Indications for caesarean section
Failure to progress 3 (4.6%) 2 (3.2%) P=0.682**
Fetal heart rate abnormality 2 (3%) 5 (7.9%) P=0.081**
Mean interval between first 
insertion and delivery
<12 hrs 36 (60%) 34 (60.7%) P=0.871***
12‑24 hrs 18 (30%) 21 (33.3%) P=0.781***
>24 hrs 6 (10%) 1 (1.8%) P=0.063***
Mean induction‑delivery interval
Mean (minutes) 885±582 754±362 P=0.152***
Mean (hours) 14.7±9.7 12.6±6.1 
No of doses (mean) 1.8±1.1 1.7±0.7 P=0.689***
*Chi square‑test, **Fisher’s exact test, ***Student’s t test
Table 3: Adverse labour outcome





None 55 (84.6%) 40 (63.5%) P=0.578*
Tachysystole 0 (0.0%) 2 (3.2%) P=0.036**
Precipitate labour 3 (4.6%) 5 (7.9%) P=0.041**
Fetal heart rate abnormality 4 (6.2%) 10 (15.9%) P=0.038**
Meconium staining of liquor 0 (0.0%) 6 (9.5%) P=0.035**
Vomiting 2 (3.1%) 0 (0.0%) P=0.007**
*X2, **Fisher’s exact test
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Discussion
The result of this study further supports the efficacy of 
misoprostol as a cervical ripening and labour‑ inducing 
agents with 85% and 95% for 25 µg and 50 µg respectively 
achieving vaginal deliveries. This result is comparable to 
the report of El‑Sharbiny et al.,[5] in which 82% and 86% 
respectively were reported.
The findings of this study shows that labour outcomes 
such as the need for oxytocin augmentation and duration 
to achieve active labour agreed with other studies[10‑13] in 
which 50 µg dose demonstrated significant advantage. 
However, this study could not demonstrate a statistically 
significant difference in the induction‑to‑delivery interval 
between the two groups, although the interval was shorter 
with 50 µg dose group. A similar finding was reported by 
Meydanli et al.,[6] in which they reported (685 ± 201 min 
versus 627 ± 177 min; P = 0.09) respectively.
A major factor in Meydanli’s study was the restriction of 
indication to post‑term pregnancies, to the exclusion of 
other common indications for induction of labour.[6] Though 
our study was not limited to post‑term pregnancies, the final 
analysis showed that this was the most common indication, 
with 73% in our study. This proportion is high when 
compared to the studies of How et al.,[14] and EL‑Sharbiny 
et al.,[5] in which post‑term pregnancies constituted 20% 
and 27%, respectively. Both these studies[5,14] reported 
significantly shorter induction‑to‑delivery interval for 
women who received 50 µg of misoprostol.
If the above factor is considered, indeed heterogeneity in 
the indications for induction of labour in our study might 
be a factor in the differences observed in the studies of 
How et al.,[14] and EL‑Sharbiny et al.,[5] Farah et al.,[15] also 
reported no significantly shorter induction‑to‑delivery 
interval between 25 µg and 50 µg groups, though with 3 
hours dosing interval. The reported values of 895 ± 572 min 
versus 787 ± 538 min for 25 µg and 50 µg respectively, are 
similar to our own values.
The finding of similar caesarean section rate (8% versus 
11%) between the two groups were comparable to those 
reported by Sanchez‑Ramos et al.,[16] (19.1 versus 18.9%), 
El‑Sharbiny[5] (17.2% versus 14.2%) and Saxena et al., (30% 
versus 30%).[17] The incidence of tachysystole was higher 
with 50 µg in this study (0.0 versus 3.2%). This complication 
has been a contentious issue in the safety profile of 
misoprostol as a cervical‑ripening agent[18,19] The incidence 
rate of 3.2% in this study is lower than 20.8% reported by 
Sanchez‑Ramos et al.,[12] and 25% by Has et al.,[13] The lower 
incidence may be due to strict protocol criteria of 6 hours 
dosing interval and not commencing oxytocin augmentation 
earlier than 4 hours after the last dose of misoprostol when 
necessary.[2,20]
The higher rate of fetal heart rate abnormalities (reported 
as fetal distress) in this study (16% for 50 µg) compared 
to 4.5% reported by Liu et al.,[21] may be partly due to the 
method of diagnosis of these abnormalities as this study 
relied solely on Pinnard stethoscope for fetal monitoring as 
obtained in many low resource settings.[22] This might have 
increased the possibility of over diagnosis of fetal heart rate 
abnormalities. This latter point is supported by the fact that 
there was no significant difference in the Apgar scores in 
the two groups and none of the babies had Apgar score of 
less than 7 at 5 minutes.
The proportion of patients with vomiting in this study was 
unexpectedly higher in the 25 µg group. While vomiting is 
a known side‑effect of misoprostol, it is usually dose related 
and occurs in higher doses commonly used in medical 
abortions.[23] The finding in this study probably represent 
the response of the patients to other medications used in 
the management of labour mainly ergometrine, especially 
as both incidents of vomiting occurred in the third stage of 
labour. It may also represent the wide range of response to 
misoprostol in different women.[23]
The overall neonatal outcomes: Apgar score, need for 
resuscitation, admission to special care baby unit and 
indication for such admissions were similar in the two 
groups, and comparable to previous studies.[12,13,17,18]
Major limitations of this study include the non‑availability of 
25 µg and 50 µg tablets in the country at the time the study 
was conducted. The error that the method of obtaining 
these doses from the available 100 µg might have introduced 
to the study could not be quantified. Also the sample size 
of the study is small such that it has no statistical power to 
evaluate the safety of misoprostol.
We conclude that 25 µg of intra‑vaginal misoprostol is as 
effective as 50 µg in pre‑induction cervical ripening and 
appears safer; although, there is less need for oxytocin 
and that more patients achieved delivery within 24 hours 
with 50 µg dosage. The higher rate of uterine contractile 
abnormalities with 50 µg dose is of particular concern.[24] 
More studies are needed to further confirm the result of 
the study and particularly in relation to the safety profile 
of misoprostol for cervical ripening and induction of labour 
especially in low resource settings.
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